These new approaches could implement the assessment of different aspects and stages of the lung cancer history: to differentiate the histological subtypes of cancer, particularly, adenocarcinoma and squamous cell carcinoma; to predict EGFR mutation status or PD-L1 expression for the risk stratification of NSCLC patients; and to predict response to different kind of therapies [165]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.